The results showed that only IL-1-MT could be used as an independent predictor of good prognosis in COAD patients receiving ICIs (P = 0.03, HR = 0.269, 95% CI: 0.082-0.883; Figure 1A). This evidence concerns the gene IL1B and colon adenocarcinoma.